After Wedbush and Jefferies gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on Albireo Pharma today and set a price target of $80.00. The company's shares closed last Wednesday at $26.88. According to TipRanks.com, Arce is a 5-star analyst with an average return of 13.2% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $77.00, which is a 180.
https://www.tipranks.com/news/blurbs/albireo-pharma-albo-received-its-third-buy-in-a-row-5?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Albireo Pharma Charts.